CN1612689A - IgG抗体稳定的液态药物制剂 - Google Patents
IgG抗体稳定的液态药物制剂 Download PDFInfo
- Publication number
- CN1612689A CN1612689A CNA028267273A CN02826727A CN1612689A CN 1612689 A CN1612689 A CN 1612689A CN A028267273 A CNA028267273 A CN A028267273A CN 02826727 A CN02826727 A CN 02826727A CN 1612689 A CN1612689 A CN 1612689A
- Authority
- CN
- China
- Prior art keywords
- preparation
- antibody
- clarifies
- sample
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (13)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33750901P | 2001-11-08 | 2001-11-08 | |
US60/337,509 | 2001-11-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1612689A true CN1612689A (zh) | 2005-05-04 |
CN1292655C CN1292655C (zh) | 2007-01-03 |
Family
ID=23320826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028267273A Expired - Fee Related CN1292655C (zh) | 2001-11-08 | 2002-11-08 | IgG抗体稳定的液态药物制剂 |
Country Status (17)
Country | Link |
---|---|
US (3) | US20030138417A1 (zh) |
EP (1) | EP1441589B1 (zh) |
JP (2) | JP5290489B2 (zh) |
KR (1) | KR100913714B1 (zh) |
CN (1) | CN1292655C (zh) |
AT (1) | ATE556591T1 (zh) |
AU (1) | AU2002363339B2 (zh) |
CA (1) | CA2466034C (zh) |
CY (1) | CY2016044I1 (zh) |
DK (1) | DK1441589T3 (zh) |
ES (1) | ES2392073T3 (zh) |
HK (1) | HK1074750A1 (zh) |
IL (2) | IL161677A0 (zh) |
LU (1) | LU93314I2 (zh) |
NZ (1) | NZ532896A (zh) |
PT (1) | PT1441589E (zh) |
WO (1) | WO2003039485A2 (zh) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101821403A (zh) * | 2007-10-24 | 2010-09-01 | 中外制药株式会社 | 用于异种蛋白制备的细胞及使用所述细胞的制备方法 |
CN102245639A (zh) * | 2008-12-10 | 2011-11-16 | 诺瓦提斯公司 | 抗体制剂 |
US8697397B2 (en) | 2007-08-07 | 2014-04-15 | Chugai Seiyaku Kabushiki Kaisha | Method of producing heterogeneous protein |
CN103781493A (zh) * | 2011-06-30 | 2014-05-07 | 霍夫曼-拉罗奇有限公司 | 抗c-met抗体配制剂 |
US8741601B2 (en) | 2009-04-22 | 2014-06-03 | Chugai Seiyaku Kabushiki Kaisha | Method for producing a cell capable of high-yield production of heteroproteins |
US8796007B2 (en) | 2007-03-15 | 2014-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method for production of polypeptide |
CN104524566A (zh) * | 2010-09-17 | 2015-04-22 | 巴克斯特国际公司 | 通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白 |
US9238687B2 (en) | 2006-04-13 | 2016-01-19 | Chugai Seiyaku Kabushiki Kaisha | Method for recombinant production of a desired polypeptide using a mammalian cell co-expressing a taurine transporter polypeptide |
CN106661111A (zh) * | 2014-05-16 | 2017-05-10 | 葛兰素史密斯克莱知识产权管理有限公司 | 抗体制剂 |
CN106659785A (zh) * | 2014-05-07 | 2017-05-10 | 武田有限公司 | 包含gm‑csf中和化合物的液体制剂 |
US9802993B2 (en) | 2007-10-15 | 2017-10-31 | Chugai Seiyaku Kabushiki Kaisha | Method for producing a cell for protein production by treating a cell overexpressing a taurine transporter with methotrexate |
CN107787229A (zh) * | 2015-06-17 | 2018-03-09 | 伊莱利利公司 | 抗‑cgrp抗体制剂 |
CN104870016B (zh) * | 2012-12-13 | 2018-05-08 | 默沙东有限公司 | 工程化的抗IL-23p19抗体的溶液制剂 |
CN108718522A (zh) * | 2016-02-23 | 2018-10-30 | 赛森生物股份有限公司 | Il-6拮抗剂制剂及其用途 |
CN110769851A (zh) * | 2017-02-24 | 2020-02-07 | 金德雷德生物科学股份有限公司 | 兽用抗il31抗体 |
CN110831621A (zh) * | 2017-04-18 | 2020-02-21 | 雷迪博士实验室有限公司 | 稳定的液体药物组合物 |
WO2020108497A1 (zh) * | 2018-11-29 | 2020-06-04 | 和铂医药(香港)有限公司 | 一种抗pd-l1抗体制剂 |
US10745475B2 (en) | 2013-08-30 | 2020-08-18 | Takeda Gmbh | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
Families Citing this family (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
IL155002A0 (en) * | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
WO2003039485A2 (en) * | 2001-11-08 | 2003-05-15 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US20040002451A1 (en) * | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
AU2003251592A1 (en) * | 2002-06-21 | 2004-01-06 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
US20040208869A1 (en) * | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Uses of anti-integrin alphanubeta3 antibody formulations |
US20040208870A1 (en) * | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Stabilized high concentration anti-integrin alphanubeta3 antibody formulations |
KR101235507B1 (ko) * | 2003-02-28 | 2013-02-20 | 추가이 세이야쿠 가부시키가이샤 | 단백질을 함유하는 안정화 제제 |
EP3178492A1 (en) | 2003-04-04 | 2017-06-14 | Genentech, Inc. | High concentration antibody and protein formulations |
US20050158303A1 (en) * | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
CA2544532C (en) * | 2003-11-28 | 2015-06-16 | Micromet Ag | Compositions comprising polypeptides |
US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
EP1709080B1 (en) * | 2004-01-09 | 2011-03-09 | Pfizer Inc. | ANTIBODIES TO MAdCAM |
US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
JP2008523815A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのヒト化アミロイドβ抗体 |
GT200600033A (es) * | 2005-01-28 | 2006-10-25 | Formulaciones liquidas estabilizadas de polipeptido | |
GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
AU2014240252B2 (en) * | 2005-03-08 | 2016-10-06 | Pfizer Products Inc | Anti-CTLA-4 Antibody Compositions |
AU2012200203B2 (en) * | 2005-03-08 | 2014-07-03 | Pfizer Products Inc. | Anti-CTLA-4 Antibody Compositions |
AU2006220828A1 (en) * | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Anti-MAdCAM antibody compositions |
CN102614134B (zh) | 2005-03-25 | 2016-09-07 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
MX2007014148A (es) * | 2005-05-19 | 2008-01-11 | Amgen Inc | Composiciones y metodos para incrementar la estabilidad de anticuerpos. |
AU2006259664A1 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
WO2007002543A2 (en) * | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
EP1909838A2 (en) * | 2005-07-29 | 2008-04-16 | Amgen Inc. | Formulations that inhibit protein aggregation |
CA2615122A1 (en) * | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
US20100209437A1 (en) * | 2005-09-12 | 2010-08-19 | Greg Elson | Anti-CD3 Antibody Fromulations |
KR101105871B1 (ko) * | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
AU2006302254B2 (en) * | 2005-10-06 | 2011-05-26 | Xencor, Inc. | Optimized anti-CD30 antibodies |
CN101378782A (zh) * | 2005-12-21 | 2009-03-04 | 惠氏公司 | 粘度降低的蛋白质制剂及其用途 |
US8569278B2 (en) | 2006-01-25 | 2013-10-29 | Taro Pharmaceuticals North America, Inc. | Anti-histamine compositions and use thereof |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
CN102887955A (zh) | 2006-04-05 | 2013-01-23 | 艾博特生物技术有限公司 | 抗体纯化 |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
KR101317235B1 (ko) | 2006-04-21 | 2013-10-15 | 조마 테크놀로지 리미티드 | 길항제 항-cd40 항체 제약 조성물 |
TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
AU2016204760A1 (en) * | 2006-04-26 | 2016-07-28 | Wyeth Llc | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
AU2014268186C1 (en) * | 2006-04-26 | 2017-12-07 | Wyeth Llc | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
LT2944306T (lt) | 2006-06-16 | 2021-02-25 | Regeneron Pharmaceuticals, Inc. | Vfgf antagonisto kompozicijos, tinkamos įvedimui intravitrealiniu būdu |
AU2012200284B2 (en) * | 2006-10-06 | 2014-03-06 | Amgen Inc. | Stable Antibody Formulations |
PE20081179A1 (es) * | 2006-10-06 | 2008-09-29 | Amgen Inc | Formulaciones estables de anticuerpos egfr |
US7705132B2 (en) * | 2006-10-20 | 2010-04-27 | Amgen Inc. | Stable polypeptide formulations |
US20080213282A1 (en) * | 2006-12-21 | 2008-09-04 | Jaby Jacob | Formulations |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
WO2009009406A1 (en) * | 2007-07-06 | 2009-01-15 | Smithkline Beecham Corporation | Antibody formulations |
JP5889529B2 (ja) | 2007-07-27 | 2016-03-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | アミロイド原性疾患の処置 |
PE20090711A1 (es) | 2007-09-26 | 2009-07-15 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo mutante |
ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
WO2009041621A1 (ja) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 抗il-6レセプター抗体 |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
WO2009064838A1 (en) * | 2007-11-15 | 2009-05-22 | Amgen, Inc. | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
CN101951885A (zh) * | 2007-12-28 | 2011-01-19 | 生物发明国际公司 | 制剂 |
WO2010089522A1 (en) * | 2009-07-16 | 2010-08-12 | Arecor Limited | Stable formulation of a therapeutic protein |
EP2328607A1 (en) | 2008-07-16 | 2011-06-08 | Arecor Limited | Stable formulation of a therapeutic protein |
PE20110302A1 (es) * | 2008-09-19 | 2011-05-21 | Hoffmann La Roche | Formulacion farmaceutica de un anticuerpo contra p-selectina |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
AU2009319856A1 (en) * | 2008-11-28 | 2010-06-03 | Abbvie Inc. | Stable antibody compositions and methods for stabilizing same |
US10005830B2 (en) | 2009-03-05 | 2018-06-26 | Ablynx N.V. | Antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
BRPI1006519A2 (pt) * | 2009-03-06 | 2016-08-09 | Genentech Inc | formulação de anticorpos |
WO2010115728A2 (en) * | 2009-03-30 | 2010-10-14 | F. Hoffmann-La Roche Ag | A method for avoiding glass fogging |
JP2012526121A (ja) * | 2009-05-04 | 2012-10-25 | アボツト・バイオテクノロジー・リミテツド | ヒト抗tnfアルファ抗体の安定した高蛋白質濃度製剤 |
JP2012533548A (ja) * | 2009-07-14 | 2012-12-27 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 組成物における黄色形成および過酸化物形成を阻害する方法 |
CA2771335A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Biotherapeutics Corp. | Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients |
EP3438126B1 (en) * | 2009-09-03 | 2020-08-19 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
US8821879B2 (en) | 2009-09-04 | 2014-09-02 | Xoma Technology Ltd. | Anti-botulism antibody coformulations |
WO2011028962A1 (en) * | 2009-09-04 | 2011-03-10 | Xoma Technology Ltd. | Antibody coformulations |
AU2010313318A1 (en) | 2009-10-30 | 2012-04-12 | Abbott Biotherapeutics Corp. | Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients |
MX2012007676A (es) * | 2009-12-29 | 2012-08-03 | Hoffmann La Roche | Nueva formulacion de anticuerpo. |
PT2521568T (pt) | 2010-01-06 | 2018-10-26 | Dyax Corp | Proteínas de ligação à calicreína plasmática |
US20120294866A1 (en) * | 2010-01-19 | 2012-11-22 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for proteins |
TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
SG10201903166PA (en) | 2010-03-01 | 2019-05-30 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
EP2542221A4 (en) * | 2010-03-01 | 2013-10-23 | Cytodyn Inc | CONCENTRATED PROTEIN FORMULATIONS AND USES THEREOF |
DK2575870T3 (en) | 2010-06-04 | 2017-02-13 | Wyeth Llc | vaccine Formulations |
FR2961107B1 (fr) * | 2010-06-15 | 2012-07-27 | Lab Francais Du Fractionnement | Composition d'immunoglobulines humaines stabilisee |
JO3400B1 (ar) | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
WO2012061448A1 (en) | 2010-11-04 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Anti-il-23 antibodies |
NZ609469A (en) | 2010-11-11 | 2015-02-27 | Abbvie Biotechnology Ltd | Improved high concentration anti-tnfα antibody liquid formulations |
EP2471554A1 (en) * | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
AU2012204202A1 (en) | 2011-01-06 | 2013-07-11 | Dyax Corp. | Plasma kallikrein binding proteins |
KR20220097542A (ko) | 2011-01-13 | 2022-07-07 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
EP2697369B1 (en) | 2011-03-25 | 2018-06-27 | F.Hoffmann-La Roche Ag | Novel protein purification methods |
UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
EP4088736A1 (en) | 2011-10-25 | 2022-11-16 | Prothena Biosciences Limited | Humanized anti-amyloid antibody formulations and methods |
US10316095B2 (en) * | 2012-02-16 | 2019-06-11 | Santarus, Inc. | Antibody formulations |
EP4039275A1 (en) * | 2012-05-03 | 2022-08-10 | Boehringer Ingelheim International GmbH | Anti-il-23p19 antibodies |
SG10201709555SA (en) * | 2012-05-18 | 2017-12-28 | Genentech Inc | High-concentration monoclonal antibody formulations |
US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
MX2015000337A (es) * | 2012-07-09 | 2015-09-25 | Coherus Biosciences Inc | Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles. |
FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
PL2892550T3 (pl) | 2012-09-07 | 2020-07-27 | Coherus Biosciences, Inc. | Stabilne wodne formulacje adalimumabu |
EP2727602A1 (en) | 2012-10-31 | 2014-05-07 | Takeda GmbH | Method for preparation of a high concentration liquid formulation of an antibody |
CA2902289A1 (en) * | 2013-03-15 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Low concentration antibody formulations |
BR112015023084A2 (pt) | 2013-03-15 | 2017-11-21 | Abbvie Biotechnology Ltd | anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira procariota e eucariota, método para a produção de um anticorpo anti-cd25 ou fragmento ligante anti-cd25, e, uso de um anticorpo anti-cd25 monoclonal de um conjugado anticorpo-droga ou de uma composição farmacêutica |
CA3208188A1 (en) | 2013-03-15 | 2014-09-25 | Takeda Pharmaceutical Company Limited | Anti-plasma kallikrein antibodies |
WO2014144935A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Biotherapeutics Inc. | Anti-cd25 antibodies and their uses |
CN103217525B (zh) * | 2013-03-21 | 2015-04-29 | 上海执诚生物科技股份有限公司 | 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途 |
KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
KR102372245B1 (ko) | 2013-11-21 | 2022-03-08 | 젠맵 에이/에스 | 항체-약물 접합체 동결건조 제제 |
AU2015209481C1 (en) | 2014-01-21 | 2020-10-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
IL295414A (en) | 2014-03-27 | 2022-10-01 | Takeda Pharmaceuticals Co | Compositions and methods for treating macular edema as a result of diabetes |
US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
WO2015198199A1 (en) | 2014-06-23 | 2015-12-30 | Novartis Ag | Hsa-gdf-15 fusion polypeptide and use thereof. |
EP3157942B1 (en) | 2014-06-23 | 2020-06-17 | Novartis AG | Site specific protein modifications |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
US10507241B2 (en) | 2014-07-24 | 2019-12-17 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of IL-23A related diseases |
TWI711629B (zh) | 2014-09-03 | 2020-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | 靶向IL-23A與TNF-α之化合物及其用途 |
MD20170055A2 (ro) | 2014-10-24 | 2017-09-30 | Merck Sharp & Dohme Corp | Co-agonişti ai receptorilor glucagonului şi GLP-1 |
SI3215530T1 (sl) | 2014-11-07 | 2020-02-28 | Sesen Bio, Inc. | Izboljšana protitelesa IL-6 |
AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
EP3247405B1 (en) | 2015-01-23 | 2019-07-17 | Novartis AG | Synthetic apelin fatty acid conjugates with improved half-life |
AU2016257023B2 (en) | 2015-05-07 | 2022-06-30 | Swedish Orphan Biovitrum Ag | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers |
US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
PT3334747T (pt) | 2015-08-13 | 2023-12-12 | Amgen Inc | Formulação de gonadotrofina líquida estável |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
KR102343004B1 (ko) | 2015-12-03 | 2021-12-24 | 리제너론 파마슈티칼스 인코포레이티드 | 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법 |
WO2017096262A1 (en) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
KR20180094028A (ko) | 2015-12-11 | 2018-08-22 | 다이액스 코포레이션 | 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도 |
EP3393494A1 (en) | 2015-12-22 | 2018-10-31 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
BR112018014277A2 (pt) | 2016-01-13 | 2018-12-18 | Genmab As | formulação, e, método de preparação de uma solução injetável de um axl-adc |
WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
WO2018027195A1 (en) * | 2016-08-05 | 2018-02-08 | Abbvie Biotherapeutics Inc. | Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same |
AU2017345490B2 (en) | 2016-10-21 | 2022-07-07 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
US11236146B2 (en) | 2016-10-28 | 2022-02-01 | Celltrion Inc. | Stable pharmaceutical formulation |
GB201703062D0 (en) * | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
WO2018156367A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
TW202228779A (zh) * | 2017-03-01 | 2022-08-01 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
TWI775827B (zh) * | 2017-03-31 | 2022-09-01 | 日商明治製菓藥業股份有限公司 | 水性製劑及裝入注射器之水性製劑以及抗體蛋白去凝集劑及抗體蛋白去凝集方法 |
MX2019013072A (es) | 2017-05-02 | 2019-12-16 | Merck Sharp & Dohme | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
US11654194B2 (en) * | 2017-05-16 | 2023-05-23 | Jiangsu Hengrui Medicine Co., Ltd. | PD-L1 antibody pharmaceutical composition and use thereof |
PE20200616A1 (es) | 2017-07-14 | 2020-03-11 | Pfizer | ANTICUERPOS CONTRA MAdCAM |
EP3678700B1 (en) | 2017-09-05 | 2024-06-19 | Merck Sharp & Dohme LLC | Compounds for reducing the viscosity of biological formulations |
WO2019055902A1 (en) * | 2017-09-18 | 2019-03-21 | Amgen Inc. | FUSION PROTEIN FORMULATIONS VEGFR-FC |
CN111601613A (zh) | 2017-12-22 | 2020-08-28 | 诺华股份有限公司 | 用fgf21变体治疗代谢障碍的方法 |
MA52570A (fr) | 2018-05-10 | 2021-03-17 | Regeneron Pharma | Formulations contenant des protéines de fusion du récepteur vegf à haute concentration |
US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
EP3887393A1 (en) | 2018-11-26 | 2021-10-06 | Novartis AG | Lpl-gpihbp1 fusion polypeptides |
US20220098252A1 (en) | 2019-01-25 | 2022-03-31 | Ospedale San Raffaele S.R.L. | Inhibitor of dux4 and uses thereof |
WO2021011404A1 (en) * | 2019-07-12 | 2021-01-21 | Contrafect Corporation | Therapeutic protein formulations comprising antibodies and uses thereof |
GB201913697D0 (en) | 2019-09-23 | 2019-11-06 | King S College London | DAP10/DAP12 fusion polypeptides |
JP2023512446A (ja) * | 2020-01-13 | 2023-03-27 | アプティーボ リサーチ アンド デベロップメント エルエルシー | 治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物 |
GB202003277D0 (en) | 2020-03-06 | 2020-04-22 | King S College London | Therapeutic agents |
EP4153130A1 (en) * | 2020-05-19 | 2023-03-29 | F. Hoffmann-La Roche AG | The use of chelators for the prevention of visible particle formation in parenteral protein solutions |
GB202007655D0 (en) | 2020-05-22 | 2020-07-08 | King S College London | Chimeric nkg2d protein |
CA3212856A1 (en) | 2021-03-23 | 2022-09-29 | John Maher | Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof |
GB202214120D0 (en) | 2022-09-27 | 2022-11-09 | King S College London | Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof |
EP4389762A1 (en) | 2022-12-23 | 2024-06-26 | Ospedale San Raffaele S.r.l. | Inhibitors of dux4 activity and their use in therapy. |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5091178A (en) * | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
WO1989011297A1 (en) | 1988-05-27 | 1989-11-30 | Centocor, Inc. | Freeze-dried formulation for antibody products |
EP0448605A4 (en) * | 1988-12-15 | 1991-11-21 | Invitron Corporation | Use of basic amino acids to solubilize immunoglobulins |
JPH04504253A (ja) | 1989-03-27 | 1992-07-30 | セントカー・インコーポレーテツド | IgM抗体の安定化のための配合物 |
US6165467A (en) * | 1991-07-20 | 2000-12-26 | Yoshihide Hagiwara | Stabilized human monoclonal antibody preparation |
AU695129B2 (en) * | 1995-02-06 | 1998-08-06 | Genetics Institute, Llc | Formulations for IL-12 |
CN100360184C (zh) * | 1995-07-27 | 2008-01-09 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白质制剂 |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9610992D0 (en) * | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
DE69810481T2 (de) * | 1997-06-13 | 2003-09-25 | Genentech Inc | Stabilisierte antikörperformulierung |
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
JP4841038B2 (ja) | 1999-03-25 | 2011-12-21 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ヒトil−12に結合するヒト抗体およびその産生法 |
US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
IL155002A0 (en) * | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
WO2003039485A2 (en) * | 2001-11-08 | 2003-05-15 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
-
2002
- 2002-11-08 WO PCT/US2002/036093 patent/WO2003039485A2/en active Application Filing
- 2002-11-08 EP EP02802895A patent/EP1441589B1/en not_active Expired - Lifetime
- 2002-11-08 JP JP2003541777A patent/JP5290489B2/ja not_active Expired - Fee Related
- 2002-11-08 PT PT02802895T patent/PT1441589E/pt unknown
- 2002-11-08 DK DK02802895.9T patent/DK1441589T3/da active
- 2002-11-08 CA CA2466034A patent/CA2466034C/en not_active Expired - Lifetime
- 2002-11-08 ES ES02802895T patent/ES2392073T3/es not_active Expired - Lifetime
- 2002-11-08 US US10/291,528 patent/US20030138417A1/en not_active Abandoned
- 2002-11-08 AT AT02802895T patent/ATE556591T1/de active
- 2002-11-08 NZ NZ532896A patent/NZ532896A/en not_active IP Right Cessation
- 2002-11-08 AU AU2002363339A patent/AU2002363339B2/en not_active Ceased
- 2002-11-08 KR KR1020047006962A patent/KR100913714B1/ko active IP Right Grant
- 2002-11-08 CN CNB028267273A patent/CN1292655C/zh not_active Expired - Fee Related
- 2002-11-08 IL IL16167702A patent/IL161677A0/xx unknown
-
2004
- 2004-04-29 IL IL161677A patent/IL161677A/en active IP Right Grant
-
2005
- 2005-08-17 HK HK05107139A patent/HK1074750A1/xx not_active IP Right Cessation
-
2010
- 2010-11-24 US US12/954,512 patent/US20110070231A1/en not_active Abandoned
- 2010-12-10 JP JP2010276222A patent/JP2011068675A/ja active Pending
-
2011
- 2011-09-06 US US13/226,372 patent/US8465739B2/en not_active Expired - Lifetime
-
2016
- 2016-11-17 LU LU93314C patent/LU93314I2/fr unknown
- 2016-12-09 CY CY2016044C patent/CY2016044I1/el unknown
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9238687B2 (en) | 2006-04-13 | 2016-01-19 | Chugai Seiyaku Kabushiki Kaisha | Method for recombinant production of a desired polypeptide using a mammalian cell co-expressing a taurine transporter polypeptide |
US9181540B2 (en) | 2007-03-15 | 2015-11-10 | Chugai Seiyaku Kabushiki Kaisha | Method for production of polypeptide |
US8796007B2 (en) | 2007-03-15 | 2014-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method for production of polypeptide |
US9499618B2 (en) | 2007-08-07 | 2016-11-22 | Chugai Seiyaku Kabushiki Kaisha | Method of producing heterogeneous protein |
US8697397B2 (en) | 2007-08-07 | 2014-04-15 | Chugai Seiyaku Kabushiki Kaisha | Method of producing heterogeneous protein |
US9284374B2 (en) | 2007-08-07 | 2016-03-15 | Chugai Seiyaku Kabushiki Kaisha | Method of producing heterogeneous protein |
US9802993B2 (en) | 2007-10-15 | 2017-10-31 | Chugai Seiyaku Kabushiki Kaisha | Method for producing a cell for protein production by treating a cell overexpressing a taurine transporter with methotrexate |
CN101821403A (zh) * | 2007-10-24 | 2010-09-01 | 中外制药株式会社 | 用于异种蛋白制备的细胞及使用所述细胞的制备方法 |
US9068212B2 (en) | 2007-10-24 | 2015-06-30 | Chugai Seiyaku Kabushiki Kaisha | Method for producing a polypeptide using a cell that overexpresses a bicarbonate transporter |
CN104399076B (zh) * | 2008-12-10 | 2021-09-14 | 诺华股份有限公司 | 抗体制剂 |
CN104399076A (zh) * | 2008-12-10 | 2015-03-11 | 诺华股份有限公司 | 抗体制剂 |
CN102245639A (zh) * | 2008-12-10 | 2011-11-16 | 诺瓦提斯公司 | 抗体制剂 |
US8741601B2 (en) | 2009-04-22 | 2014-06-03 | Chugai Seiyaku Kabushiki Kaisha | Method for producing a cell capable of high-yield production of heteroproteins |
CN104524566A (zh) * | 2010-09-17 | 2015-04-22 | 巴克斯特国际公司 | 通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白 |
CN107090038A (zh) * | 2011-06-30 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 抗c‑met抗体配制剂 |
US9487589B2 (en) | 2011-06-30 | 2016-11-08 | Genentech, Inc. | Anti-c-met-antibody formulations |
CN103781493A (zh) * | 2011-06-30 | 2014-05-07 | 霍夫曼-拉罗奇有限公司 | 抗c-met抗体配制剂 |
CN104870016B (zh) * | 2012-12-13 | 2018-05-08 | 默沙东有限公司 | 工程化的抗IL-23p19抗体的溶液制剂 |
US10745475B2 (en) | 2013-08-30 | 2020-08-18 | Takeda Gmbh | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
US11795216B2 (en) | 2013-08-30 | 2023-10-24 | Takeda Pharmaceutical Company Limited | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
CN106659785A (zh) * | 2014-05-07 | 2017-05-10 | 武田有限公司 | 包含gm‑csf中和化合物的液体制剂 |
CN106659785B (zh) * | 2014-05-07 | 2021-04-30 | 武田有限公司 | 包含gm-csf中和化合物的液体制剂 |
CN106661111A (zh) * | 2014-05-16 | 2017-05-10 | 葛兰素史密斯克莱知识产权管理有限公司 | 抗体制剂 |
TWI725973B (zh) * | 2015-06-17 | 2021-05-01 | 美商美國禮來大藥廠 | 抗-cgrp抗體調配物 |
CN107787229A (zh) * | 2015-06-17 | 2018-03-09 | 伊莱利利公司 | 抗‑cgrp抗体制剂 |
CN114948847A (zh) * | 2015-06-17 | 2022-08-30 | 伊莱利利公司 | 抗-cgrp抗体制剂 |
CN108718522A (zh) * | 2016-02-23 | 2018-10-30 | 赛森生物股份有限公司 | Il-6拮抗剂制剂及其用途 |
CN110769851A (zh) * | 2017-02-24 | 2020-02-07 | 金德雷德生物科学股份有限公司 | 兽用抗il31抗体 |
US11673946B2 (en) | 2017-02-24 | 2023-06-13 | Kindred Biosciences, Inc. | Methods of treating a companion animal species comprising administering anti-IL31 antibodies |
US11697683B2 (en) | 2017-02-24 | 2023-07-11 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
CN110769851B (zh) * | 2017-02-24 | 2023-12-08 | 金德雷德生物科学股份有限公司 | 兽用抗il31抗体 |
CN110831621A (zh) * | 2017-04-18 | 2020-02-21 | 雷迪博士实验室有限公司 | 稳定的液体药物组合物 |
WO2020108497A1 (zh) * | 2018-11-29 | 2020-06-04 | 和铂医药(香港)有限公司 | 一种抗pd-l1抗体制剂 |
Also Published As
Publication number | Publication date |
---|---|
EP1441589B1 (en) | 2012-05-09 |
DK1441589T3 (da) | 2012-08-06 |
IL161677A (en) | 2010-06-16 |
CY2016044I2 (el) | 2017-07-12 |
ES2392073T3 (es) | 2012-12-04 |
US20110318343A1 (en) | 2011-12-29 |
PT1441589E (pt) | 2012-08-13 |
US20030138417A1 (en) | 2003-07-24 |
CA2466034A1 (en) | 2003-05-15 |
LU93314I2 (zh) | 2019-11-20 |
JP5290489B2 (ja) | 2013-09-18 |
CN1292655C (zh) | 2007-01-03 |
WO2003039485A3 (en) | 2004-02-12 |
WO2003039485A2 (en) | 2003-05-15 |
KR20050044365A (ko) | 2005-05-12 |
IL161677A0 (en) | 2004-09-27 |
US8465739B2 (en) | 2013-06-18 |
AU2002363339B2 (en) | 2008-02-07 |
ATE556591T1 (de) | 2012-05-15 |
JP2005508981A (ja) | 2005-04-07 |
US20110070231A1 (en) | 2011-03-24 |
KR100913714B1 (ko) | 2009-08-24 |
CA2466034C (en) | 2012-12-18 |
NZ532896A (en) | 2007-08-31 |
EP1441589A4 (en) | 2007-07-04 |
JP2011068675A (ja) | 2011-04-07 |
EP1441589A2 (en) | 2004-08-04 |
HK1074750A1 (en) | 2005-11-25 |
CY2016044I1 (el) | 2017-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1612689A (zh) | IgG抗体稳定的液态药物制剂 | |
CN1155408C (zh) | 冷冻干燥的稳定的单克隆或多克隆抗体药物制剂 | |
US20180258178A1 (en) | Molecules with Reduced Effector Function and Extended Half-Lives, Compositions, and Uses Thereof | |
CN1798575A (zh) | 高浓度抗体和蛋白制剂 | |
CN1317303C (zh) | 抗人腱生蛋白单克隆抗体 | |
CN1993139A (zh) | 稳定的干扰素液体制剂 | |
CN1723220A (zh) | 含有免疫球蛋白fc区作为载体的药物组合物 | |
CN1537015A (zh) | 稳定的抗体液体制剂 | |
CN1186517A (zh) | 具有更长半衰期的变异多肽 | |
CN1897971A (zh) | Cd40抗体制剂和方法 | |
CN1076966A (zh) | 抗人白细胞介素-4的人性化单克隆抗体的克隆和表达 | |
CN1105728C (zh) | 用于治疗il4介导疾病的重组il4抗体 | |
CN1527726A (zh) | 红细胞生成素共轭物 | |
CN1993138A (zh) | 稳定蛋白质的方法 | |
CN1638798A (zh) | 包含抗体的溶液制剂 | |
CN1077991A (zh) | 具有人属性的抗人白细胞介素-5的单克隆抗体的设计,克隆和表达 | |
CN1361793A (zh) | 干扰素-α蛋白作为Fc融合蛋白的表达和运输 | |
CN1902222A (zh) | 具有改善药物代谢动力学的Fc-***融合蛋白质 | |
CN1878790A (zh) | 可中和的hgf表位和与其结合的中和抗体 | |
CN1200737A (zh) | 用于人治疗的重组抗cd4抗体 | |
BG108087A (bg) | Увеличено възстановяване на активни протеини | |
CN1360596A (zh) | 与b7分子发生反应的人源化免疫球蛋白及应用该免疫球蛋白的治疗方法 | |
CN1280586A (zh) | 具有高比活的*** | |
CN1589902A (zh) | 抗-LT-β-R抗体在制备药用组合物中的应用 | |
CN1816347A (zh) | 不含人血清白蛋白的稳定化干扰素液体制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1074750 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: PDL BIOLOGICAL PHARMACEUTICAL STOCK CO., LTD. Free format text: FORMER NAME OR ADDRESS: PROTEIN DESIGN LABS |
|
CP03 | Change of name, title or address |
Address after: California, USA Patentee after: PDL BIOPHARMA, Inc. Address before: California, USA Patentee before: Protein Design Labs, Inc. |
|
ASS | Succession or assignment of patent right |
Owner name: JINGMIAN DEBIOTECH SA Free format text: FORMER OWNER: PDL BIOLOGY PHARMACY STOCK CO., LTD. Effective date: 20090828 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090828 Address after: California, USA Patentee after: Crystal Biotech Address before: California, USA Patentee before: PDL BIOPHARMA, Inc. |
|
C56 | Change in the name or address of the patentee |
Owner name: EBERT BIOLOGIC THERAPEUTICS CORP. Free format text: FORMER NAME: CRYSTAL SURFACE BIOTECHNOLOGY COMPANY |
|
CP01 | Change in the name or title of a patent holder |
Address after: California, USA Patentee after: Albert Biotherapeutics Address before: California, USA Patentee before: Crystal Biotech |
|
C56 | Change in the name or address of the patentee |
Owner name: ABBVIE BIOTHERAPEUTICS INC. Free format text: FORMER NAME: ALBERT BIO-THERAPEUTICS CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: California, USA Patentee after: AbbVie Biotherapeutics Inc. Address before: California, USA Patentee before: Albert Biotherapeutics |
|
C56 | Change in the name or address of the patentee |
Owner name: ABBVIE BIOPHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: ABBVIE BIOTHERAPEUTICS INC. |
|
CP01 | Change in the name or title of a patent holder |
Address after: California, USA Patentee after: ABBVIE BIOTHERAPEUTICS Inc. Address before: California, USA Patentee before: Abbvie Biotherapeutics Inc. |
|
ASS | Succession or assignment of patent right |
Owner name: ABBVIE BIOTECHNOLOGY LTD. Free format text: FORMER OWNER: ABBVIE BIOPHARMACEUTICAL CO., LTD. Effective date: 20150821 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150821 Address after: Bermuda Hamilton Patentee after: ABBOTT BIOTECHNOLOGY LTD. Address before: California, USA Patentee before: ABBVIE BIOTHERAPEUTICS Inc. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070103 Termination date: 20211108 |
|
CF01 | Termination of patent right due to non-payment of annual fee |